Pacific Edge Ltd
NZX:PEB

Watchlist Manager
Pacific Edge Ltd Logo
Pacific Edge Ltd
NZX:PEB
Watchlist
Price: 0.171 NZD 1.18%
Market Cap: 174.8m NZD
Section:
 

Relative Value

The Relative Value of one PEB stock under the Base Case scenario is 0.24 NZD. Compared to the current market price of 0.171 NZD, Pacific Edge Ltd is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PEB Relative Value
Base Case
0.24 NZD
Undervaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8
P/S
P/S
Price to Sales
8
vs History
55
vs Industry
61
Median 3Y
5.9
Median 5Y
22.4
Industry
7.6
Forward
11.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-16.3
Industry
24.3
Forward
-4.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-17.2
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-14.8
Industry
24.3
More Details
6.7
P/B
P/B
Price to Book Value
6.7
vs History
36
vs Industry
34
Median 3Y
3.4
Median 5Y
5.2
Industry
3.2
More Details
7
EV/S
EV/S
Enterprise Value to Sales
7
vs History
55
vs Industry
59
Median 3Y
3.9
Median 5Y
18.5
Industry
8.4
Forward
10.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
28
Median 3Y
-2.7
Median 5Y
-11.3
Industry
6.2
Forward
-4.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
27
Median 3Y
-2.7
Median 5Y
-11.3
Industry
6.7
Forward
-4.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
30
Median 3Y
-3.4
Median 5Y
-14.2
Industry
8.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
27
Median 3Y
-3.3
Median 5Y
-12.7
Industry
6.6
More Details
24
EV/IC
EV/IC
Enterprise Value to IC
24
vs History
55
vs Industry
21
Median 3Y
12.2
Median 5Y
49.5
Industry
5.3
More Details

Multiples Across Competitors

PEB Competitors Multiples
Pacific Edge Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Pacific Edge Ltd
NZX:PEB
174.8m NZD 8 -5.8 -4.8 -4.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 234 466 -162 711.3 -197 583.5 -195 328.8
US
Abbvie Inc
NYSE:ABBV
413.6B USD 6.9 176.2 17 24.1
US
Amgen Inc
NASDAQ:AMGN
183.9B USD 5.1 26.3 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
156.4B USD 5.4 19.3 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.6B USD 9.4 30.1 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 057.8 -525.1 -571.8 -556.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.1B USD 5.3 16.4 15.6 17.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.6B USD 24.6 -189.9 -475.2 -326.2
AU
CSL Ltd
ASX:CSL
87.2B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
48.8B EUR 15.7 36.9 64.1 65.8
P/S Multiple
Revenue Growth P/S to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average P/S: 3 112 418.9
8
26%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 234 466
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.9
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
10%
0.9
US
E
Epizyme Inc
F:EPE
2 057.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
5%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.6
44%
0.6
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
15.7
46%
0.3
P/E Multiple
Earnings Growth PEG
NZ
Pacific Edge Ltd
NZX:PEB
Average P/E: 46.3
Negative Multiple: -5.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 711.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
176.2
89%
2
US
Amgen Inc
NASDAQ:AMGN
26.3
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.3
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -189.9 N/A N/A
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
36.9
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBITDA: 23.3
Negative Multiple: -4.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 583.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -571.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
9%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -475.2 N/A N/A
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
64.1
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBIT: 25.5
Negative Multiple: -4.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 328.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.2 N/A N/A
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
65.8
N/A N/A

See Also

Summary
PEB intrinsic value, competitors valuation, and company profile.
DCF Valuation
PEB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PEB stock valuation using valuation multiples.
Wall Street Estimates
PEB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PEB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 297,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.